Multiple pituitary adenomas in Cushing's disease.

Double, synchronous pituitary adenomas causing acromegaly and Cushing's disease. A case report and review of literature. Endocr Pathol (2013) 1.43

Multiple Pituitary Adenomas: A Systematic Review. Front Endocrinol (Lausanne) (2016) 0.84

Cushing's syndrome in multiple endocrine neoplasia type 1. Clin Endocrinol (Oxf) (2012) 0.81

Isolated double adrenocorticotropic hormone-secreting pituitary adenomas: A case report and review of the literature. Oncol Lett (2016) 0.80

Multiple pituitary adenomas. J Neurosurg (2000) 0.76

Diagnostic usefulness of 3 tesla MRI of the brain for cushing disease in a child. Clin Pediatr Endocrinol (2011) 0.75

Different imaging characteristics of concurrent pituitary adenomas in a patient with Cushing's disease. J Clin Neurosci (2015) 0.75

Retrospective Analysis of Cushing's Disease with or without Hyperprolactinemia. Int J Endocrinol (2014) 0.75

An unusual presentation of pediatric Cushing disease: recurrent corticotropinoma of the posterior pituitary lobe. J Pediatr Endocrinol Metab (2010) 0.75

Double pituitary adenomas are most commonly associated with GH- and ACTH-secreting tumors: systematic review of the literature. Pituitary (2017) 0.75

Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A (1994) 6.61

In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science (1992) 5.47

Elucidating the pathophysiology of syringomyelia. J Neurosurg (1999) 4.43

Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci U S A (1996) 3.88

Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol (2001) 2.86

Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med (1997) 2.76

In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res (1993) 2.74

Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms. J Clin Invest (1993) 2.42

Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med (1997) 2.39

Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features: relation to hypercortisolism and corticotropin-releasing hormone. Proc Natl Acad Sci U S A (2000) 2.19

Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res (1992) 2.17

High-flow microinfusion: tissue penetration and pharmacodynamics. Am J Physiol (1994) 2.01

The metyrapone and dexamethasone suppression tests for the differential diagnosis of the adrenocorticotropin-dependent Cushing syndrome: a comparison. Ann Intern Med (1994) 2.00

Variables affecting convection-enhanced delivery to the striatum: a systematic examination of rate of infusion, cannula size, infusate concentration, and tissue-cannula sealing time. J Neurosurg (1999) 1.97

Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion. J Neurosurg (1995) 1.94

Expression of vascular permeability factor/vascular endothelial growth factor in normal rat tissues. Am J Physiol (1993) 1.93

Spinal arteriovenous malformations: a comparison of dural arteriovenous fistulas and intradural AVM's in 81 patients. J Neurosurg (1987) 1.92

Cushing's syndrome in children and adolescents. Presentation, diagnosis, and therapy. N Engl J Med (1994) 1.78

Focal delivery during direct infusion to brain: role of flow rate, catheter diameter, and tissue mechanics. Am J Physiol (1999) 1.77

Reversible acute and subacute myelopathy in patients with dural arteriovenous fistulas. Foix-Alajouanine syndrome reconsidered. J Neurosurg (1989) 1.75

Brief report: relief of spinal cord compression from vertebral hemangioma by intralesional injection of absolute ethanol. N Engl J Med (1994) 1.75

von Hippel-Lindau gene deletion detected in the stromal cell component of a cerebellar hemangioblastoma associated with von Hippel-Lindau disease. Hum Pathol (1997) 1.74

Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population. Ann Intern Med (1994) 1.70

Mechanism of dexamethasone suppression of brain tumor-associated vascular permeability in rats. Involvement of the glucocorticoid receptor and vascular permeability factor. J Clin Invest (1996) 1.63

Endolymphatic sac tumors. A source of morbid hearing loss in von Hippel-Lindau disease. JAMA (1997) 1.63

Convection-enhanced selective excitotoxic ablation of the neurons of the globus pallidus internus for treatment of parkinsonism in nonhuman primates. J Neurosurg (1999) 1.59

Symptomatic vertebral hemangiomas: treatment by means of direct intralesional injection of ethanol. Radiology (2000) 1.58

Image-guided, direct convective delivery of glucocerebrosidase for neuronopathic Gaucher disease. Neurology (2006) 1.57

Surgical interruption of intradural draining vein as curative treatment of spinal dural arteriovenous fistulas. J Neurosurg (1995) 1.56

Tumor devascularization by intratumoral ethanol injection during surgery. Technical note. J Neurosurg (1998) 1.55

Bilateral sampling of the internal jugular vein to distinguish between mechanisms of adrenocorticotropic hormone-dependent Cushing syndrome. Ann Intern Med (1998) 1.54

Direct convective delivery of macromolecules to the spinal cord. J Neurosurg (1998) 1.53

Selective excision of adenomas originating in or extending into the pituitary stalk with preservation of pituitary function. J Neurosurg (1997) 1.49

Extrapituitary parasellar microadenoma in Cushing's disease. J Clin Endocrinol Metab (1999) 1.49

The effect of fetal mesencephalon implants on primate MPTP-induced parkinsonism. Histochemical and behavioral studies. J Neurosurg (1990) 1.48

Expression and modulation of major histocompatibility antigens on murine primary brain tumor in vitro. J Neurosurg (1991) 1.46

Thyrotropin-secreting pituitary adenomas: clinical and biochemical heterogeneity. Case reports and follow-up of nine patients. Ann Intern Med (1989) 1.46

Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Hum Gene Ther (1993) 1.44

Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Life Sci (1986) 1.39

The corticotropin-releasing factor stimulation test. An aid in the evaluation of patients with Cushing's syndrome. N Engl J Med (1984) 1.36

Vascular endothelial growth factor (VEGF) modulates vascular permeability and inflammation in rat brain. J Neuropathol Exp Neurol (1999) 1.35

Direct convective delivery of macromolecules to peripheral nerves. J Neurosurg (1998) 1.35

Mechanism of 'bystander effect' killing in the herpes simplex thymidine kinase gene therapy model of cancer treatment. Gene Ther (1997) 1.33

Chronic interstitial infusion of protein to primate brain: determination of drug distribution and clearance with single-photon emission computerized tomography imaging. J Neurosurg (1997) 1.32

Mutations of the MEN1 tumor suppressor gene in pituitary tumors. Cancer Res (1997) 1.31

Neurosurgical implications of Carney complex. J Neurosurg (2000) 1.30

Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J Neurosurg (1989) 1.27

Management of the ectopic ACTH syndrome due to thoracic carcinoids. Ann Thorac Surg (1990) 1.20

Somatic mutation of TRbeta can cause a defect in negative regulation of TSH in a TSH-secreting pituitary tumor. J Clin Endocrinol Metab (2001) 1.14

Thyrotropin-secreting pituitary tumors: diagnostic criteria, thyroid hormone sensitivity, and treatment outcome in 25 patients followed at the National Institutes of Health. J Clin Endocrinol Metab (1999) 1.14

Successful treatment of a group of spinal cord arteriovenous malformations by interruption of dural fistula. J Neurosurg (1983) 1.13

Resection of suprasellar tumors by using a modified transsphenoidal approach. Report of four cases. J Neurosurg (2000) 1.13

Treatment of cranial dural arteriovenous fistulae by interruption of leptomeningeal venous drainage. J Neurosurg (1994) 1.12

Vascular permeability induced by protein product of malignant brain tumors: inhibition by dexamethasone. J Neurosurg (1987) 1.12

A comparison of the standard high dose dexamethasone suppression test and the overnight 8-mg dexamethasone suppression test for the differential diagnosis of adrenocorticotropin-dependent Cushing's syndrome. J Clin Endocrinol Metab (1994) 1.12

Evolution of VHL tumourigenesis in nerve root tissue. J Pathol (2006) 1.11

Early repeat surgery for persistent Cushing's disease. J Neurosurg (1994) 1.09

Quantification and pharmacokinetics of blood-brain barrier disruption in humans. J Neurosurg (1996) 1.06

Temporal changes in perivascular concentrations of oxyhemoglobin, deoxyhemoglobin, and methemoglobin after subarachnoid hemorrhage. J Neurosurg (1998) 1.06

Allelic loss on chromosome 11 in hereditary and sporadic tumors related to familial multiple endocrine neoplasia type 1. Cancer Res (1991) 1.06

Spinal cord swelling preceding syrinx development. Case report. J Neurosurg (2000) 1.06

Usefulness of inferior petrosal sinus venous endocrine markers in Cushing's disease. J Neurosurg (1988) 1.06

Aberrant alternative splicing of thyroid hormone receptor in a TSH-secreting pituitary tumor is a mechanism for hormone resistance. Mol Endocrinol (2001) 1.05

A simplified morning ovine corticotropin-releasing hormone stimulation test for the differential diagnosis of adrenocorticotropin-dependent Cushing's syndrome. J Clin Endocrinol Metab (1993) 1.04

Neurologic complications of petrosal sinus sampling. Radiology (1992) 1.04

Pituitary macroadenoma in a 5-year-old: an early expression of multiple endocrine neoplasia type 1. J Clin Endocrinol Metab (2000) 1.04

Role of ferrous iron chelator 2,2'-dipyridyl in preventing delayed vasospasm in a primate model of subarachnoid hemorrhage. J Neurosurg (1998) 1.04

Gene transfer technologies for malignant gliomas. Curr Opin Oncol (1999) 1.03

Recanalization of spinal arteriovenous malformations following embolization. J Neurosurg (1989) 1.02

Preoperative lateralization of ACTH-secreting pituitary microadenomas by bilateral and simultaneous inferior petrosal venous sinus sampling. N Engl J Med (1985) 1.02

Cytosolic calcium changes in endothelial cells induced by a protein product of human gliomas containing vascular permeability factor activity. J Neurosurg (1989) 1.02

The effect of thymidine kinase transduction and ganciclovir therapy on tumor vasculature and growth of 9L gliomas in rats. J Neurosurg (1994) 1.01

Repeat transsphenoidal surgery for Cushing's disease. J Neurosurg (1989) 1.01

Microvascular anatomy of dural arteriovenous abnormalities of the spine: a microangiographic study. J Neurosurg (1996) 1.00

Evidence for the involvement of a potential second tumor suppressor gene on chromosome 17 distinct from p53 in malignant astrocytomas. Cancer Res (1992) 1.00

The ovine corticotropin-releasing hormone stimulation test and the dexamethasone suppression test in the differential diagnosis of Cushing's syndrome. Ann Intern Med (1986) 0.99

Source and cause of endothelin-1 release into cerebrospinal fluid after subarachnoid hemorrhage. J Neurosurg (1997) 0.99

Toxicity studies of retroviral-mediated gene transfer for the treatment of brain tumors. J Neurosurg (1993) 0.98

The hypoplastic inferior petrosal sinus: a potential source of false-negative results in petrosal sampling for Cushing's disease. J Clin Endocrinol Metab (1999) 0.97

The corticotropin-releasing hormone test in the postoperative evaluation of patients with cushing's syndrome. J Clin Endocrinol Metab (1987) 0.97

The diagnosis of acromegaly: value of inferior petrosal sinus sampling. AJR Am J Roentgenol (1990) 0.96

Pathophysiology of hyponatremia after transsphenoidal pituitary surgery. J Neurosurg (1997) 0.96

Intramedullary Ewing sarcoma of the spinal cord: consequences of molecular diagnostics. Case report. J Neurosurg (2001) 0.96

Selective activity of phenylacetate against malignant gliomas: resemblance to fetal brain damage in phenylketonuria. Cancer Res (1994) 0.96

Production of reactive oxygen species after reperfusion in vitro and in vivo: protective effect of nitric oxide. J Neurosurg (2000) 0.96

Acute glucocorticoid deficiency is associated with plasma elevations of interleukin-6: does the latter participate in the symptomatology of the steroid withdrawal syndrome and adrenal insufficiency? J Clin Endocrinol Metab (1996) 0.96

Convective delivery of macromolecules into the naive and traumatized spinal cords of rats. J Neurosurg (1999) 0.96

Effect of intracarotid nitric oxide on primate cerebral vasospasm after subarachnoid hemorrhage. J Neurosurg (1995) 0.95

Nitric oxide mediation of chemoregulation but not autoregulation of cerebral blood flow in primates. J Neurosurg (1996) 0.95

Further characterization of malignant glioma-derived vascular permeability factor. J Neurosurg (1988) 0.95

Intraventricular immunotoxin therapy for leptomeningeal neoplasia. Neurosurgery (1997) 0.95

Neuroprotection by the stable nitroxide Tempol during reperfusion in a rat model of transient focal ischemia. J Neurosurg (2000) 0.94

Loss of nitric oxide synthase immunoreactivity in cerebral vasospasm. J Neurosurg (1996) 0.94

Pituitary adenomas in patients with Cushing disease: initial experience with Gd-DTPA-enhanced MR imaging. Radiology (1987) 0.93

Reversal and prevention of cerebral vasospasm by intracarotid infusions of nitric oxide donors in a primate model of subarachnoid hemorrhage. J Neurosurg (1997) 0.93

Proteomic profiling distinguishes astrocytomas and identifies differential tumor markers. Neurology (2006) 0.93

Pituitary microadenomas: a PET study. Radiology (1990) 0.93

Basilar venous plexus of the posterior fossa: a potential source of error in petrosal sinus sampling. Radiology (1985) 0.92

The surgical management of spinal dural vascular malformations. Neurosurg Clin N Am (1999) 0.91

Effects of nitric oxide on reactive oxygen species production and infarction size after brain reperfusion injury. Neurosurgery (2001) 0.91